Calina Bugor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Calina Bugor has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Catalina Olaru-Stavila
Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu
2 shared publications - Eugen Tcaciuc
Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu
2 shared publications - Alexandru Ferdohleb
IP Universitatea de Stat de Medicină și Farmacie „Nicolae Testemițanu
1 shared publication - Ana Maria Badarau
Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu
1 shared publication Cristina Trocin
Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu
1 shared publicationCătălin Condrea
Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu
1 shared publication
Latest Publications
- Open Access
- 1 December 2025
- Published by AO Economie, Management si Psihologie in Medicina in Public Health, Economy and Management in Medicine
- No. 2(104),p. 184-189
Etiologia carcinomului hepatocelular: analiza retrospectivă din cadrul Spitalului Clinic Republican „Timofei Moșneaga”
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer and a significant cause of global mortality. This study aims to analyze the etiological factors of HCC at the “Timofei Moșneaga” Republican Clinical Hospital (RCH) in the Republic of Moldova, in relation to trends observed in international literature. A retrospective observational study was conducted by analyzing the cases of patients admitted to the RCH “Timofei Moșneaga.” The study included 299 patients hospitalized between 2017 and 2025 with a confirmed diagnosis of HCC. Data were collected from the SIAAM information system. Selection criteria included age, sex, etiology, and stage of liver disease. The results were compared with international studies using Google Scholar and PubMed. The predominant etiological factors were viral infections: hepatitis C virus (HCV) – 29.8%, hepatitis B virus (HBV) – 17.4%, and hepatitis D virus (HDV) co-/superinfection – 17%. Non-viral factors, such as alcohol use and metabolic dysfunction-associated steatotic liver disease (MASLD), accounted for 10.37% of cases. MASLD was identified in 1.67% of cases and alcohol use in 8.7%. Approximately 89% of patients had advanced hepatic cirrhosis (Child-Pugh classes B and C). The primary cause of HCC in the Republic of Moldova remains viral etiology, although a gradual shift toward metabolic etiology is being observed in Western countries. The high prevalence of hepatic cirrhosis at HCC diagnosis highlights the urgent need for effective screening and early detection programs.
- 1 December 2025
- Published by AO Economie, Management si Psihologie in Medicina in Public Health, Economy and Management in Medicine
- No. 2(104),p. 184-189
Open AccessEtiologia carcinomului hepatocelular: analiza retrospectivă din cadrul Spitalului Clinic Republican „Timofei Moșneaga”
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer and a significant cause of global mortality. This study aims to analyze the etiological factors of HCC at the “Timofei Moșneaga” Republican Clinical Hospital (RCH) in the Republic of Moldova, in relation to trends observed in international literature. A retrospective observational study was conducted by analyzing the cases of patients admitted to the RCH “Timofei Moșneaga.” The study included 299 patients hospitalized between 2017 and 2025 with a confirmed diagnosis of HCC. Data were collected from the SIAAM information system. Selection criteria included age, sex, etiology, and stage of liver disease. The results were compared with international studies using Google Scholar and PubMed. The predominant etiological factors were viral infections: hepatitis C virus (HCV) – 29.8%, hepatitis B virus (HBV) – 17.4%, and hepatitis D virus (HDV) co-/superinfection – 17%. Non-viral factors, such as alcohol use and metabolic dysfunction-associated steatotic liver disease (MASLD), accounted for 10.37% of cases. MASLD was identified in 1.67% of cases and alcohol use in 8.7%. Approximately 89% of patients had advanced hepatic cirrhosis (Child-Pugh classes B and C). The primary cause of HCC in the Republic of Moldova remains viral etiology, although a gradual shift toward metabolic etiology is being observed in Western countries. The high prevalence of hepatic cirrhosis at HCC diagnosis highlights the urgent need for effective screening and early detection programs.
- Open Access
- 1 October 2025
- Published by AO Economie, Management si Psihologie in Medicina in Public Health, Economy and Management in Medicine
- No. 2(104),p. 41-45
Studiu pilot observațional privind scorurile non-invazive comparativ cu biopsia în aprecierea fibrozei hepatice: reflecții în contextul literaturii actuale
Serum biomarkers represent a key pillar in the non-invasive assessment of liver fibrosis. Although biopsy remains the gold standard, the APRI and FIB-4 scores have emerged as simple and accessible alternatives, particularly in healthcare systems with limited resources. The aim of the study was to evaluate the utility of the non-invasive diagnostic scores APRI and FIB-4 in identifying liver fibrosis, in comparison with histological findings from liver biopsy. The cross-sectional observational study included all patients with chronic liver disease who were hospitalized at the Republican Clinical Hospital (Chișinău) between 2019 and 2024 and underwent liver biopsy. APRI and FIB-4 scores were calculated based on clinical and biochemical data. Liver fibrosis was confirmed histologically. Results are expressed as mean ± standard error of the mean (M±SEM). The study sample included 22 patients, of whom 40.9% were male and 59.1% female, with a mean age of 44.5±2.7 years. The APRI score identified a high risk of liver fibrosis in 40.9% of patients (n=9), while the FIB-4 score indicated a high risk in 9.1% (n=2) and an intermediate risk in 22.7% (n=5). Liver fibrosis was histologically confirmed in 45.5% of patients (n=10). Discrepancies between non-invasive scores and biopsy findings may be attributed to their variable sensitivity and the characteristics of the study cohort. APRI and FIB-4 are useful tools for the initial evaluation of liver fibrosis. While APRI showed better alignment in excluding fibrosis, FIB-4 demonstrated higher accuracy in identifying advanced fibrosis and estimating intermediate risk.
- 1 October 2025
- Published by AO Economie, Management si Psihologie in Medicina in Public Health, Economy and Management in Medicine
- No. 2(104),p. 41-45
Open AccessStudiu pilot observațional privind scorurile non-invazive comparativ cu biopsia în aprecierea fibrozei hepatice: reflecții în contextul literaturii actuale
Serum biomarkers represent a key pillar in the non-invasive assessment of liver fibrosis. Although biopsy remains the gold standard, the APRI and FIB-4 scores have emerged as simple and accessible alternatives, particularly in healthcare systems with limited resources. The aim of the study was to evaluate the utility of the non-invasive diagnostic scores APRI and FIB-4 in identifying liver fibrosis, in comparison with histological findings from liver biopsy. The cross-sectional observational study included all patients with chronic liver disease who were hospitalized at the Republican Clinical Hospital (Chișinău) between 2019 and 2024 and underwent liver biopsy. APRI and FIB-4 scores were calculated based on clinical and biochemical data. Liver fibrosis was confirmed histologically. Results are expressed as mean ± standard error of the mean (M±SEM). The study sample included 22 patients, of whom 40.9% were male and 59.1% female, with a mean age of 44.5±2.7 years. The APRI score identified a high risk of liver fibrosis in 40.9% of patients (n=9), while the FIB-4 score indicated a high risk in 9.1% (n=2) and an intermediate risk in 22.7% (n=5). Liver fibrosis was histologically confirmed in 45.5% of patients (n=10). Discrepancies between non-invasive scores and biopsy findings may be attributed to their variable sensitivity and the characteristics of the study cohort. APRI and FIB-4 are useful tools for the initial evaluation of liver fibrosis. While APRI showed better alignment in excluding fibrosis, FIB-4 demonstrated higher accuracy in identifying advanced fibrosis and estimating intermediate risk.
- Open Access
- 1 December 2024
- Published by Editorial Office "Bulletin of the Academy of Sciences of Moldova. Medical Sciences" in Bulletin of the Academy of Sciences of Moldova. Medical Sciences
- Vol. 79 (2) , 116-120
Perioperative changes in quality of life in cirotic patients with portal splenopathy of surgical interest
Portal splenopathy associated with severe symptomatic hypersplenism is a frequent complication of liver cirrhosis [1, 4], often of surgical interest. Laparoscopic splenectomy and esophagogastric devascularization has gained a prominent position in the field of portal hypertension. We evaluated 156 cirrhotic patients surgically assisted in the Clinic for portal splenopathy (year 2013-2023), laparoscopic (SPLL, n=64) or conventional open (SPLT, n=92) approach, associated in 69.9% of cases (109/159), with endoscopic variceal ligation (LVE). The clinical-endo-imaging characteristics of the patients and the quality of life, according to the chronic liver disease questionnaire (SF-LDQOL), were compared between the groups, depending on the surgical method. The results demonstrate that DVA+SPL has a positive impact on the quality of life (QoL-quality of life), constant 12-18 months after the operation. The lower QoL score, for the subdomains studied 3-5 years postoperatively, can be explained by the accumulation of risk factors dominated by liver depression and possible complications.
- 1 December 2024
- Published by Editorial Office "Bulletin of the Academy of Sciences of Moldova. Medical Sciences" in Bulletin of the Academy of Sciences of Moldova. Medical Sciences
- Vol. 79 (2) , 116-120
Open AccessPerioperative changes in quality of life in cirotic patients with portal splenopathy of surgical interest
Portal splenopathy associated with severe symptomatic hypersplenism is a frequent complication of liver cirrhosis [1, 4], often of surgical interest. Laparoscopic splenectomy and esophagogastric devascularization has gained a prominent position in the field of portal hypertension. We evaluated 156 cirrhotic patients surgically assisted in the Clinic for portal splenopathy (year 2013-2023), laparoscopic (SPLL, n=64) or conventional open (SPLT, n=92) approach, associated in 69.9% of cases (109/159), with endoscopic variceal ligation (LVE). The clinical-endo-imaging characteristics of the patients and the quality of life, according to the chronic liver disease questionnaire (SF-LDQOL), were compared between the groups, depending on the surgical method. The results demonstrate that DVA+SPL has a positive impact on the quality of life (QoL-quality of life), constant 12-18 months after the operation. The lower QoL score, for the subdomains studied 3-5 years postoperatively, can be explained by the accumulation of risk factors dominated by liver depression and possible complications.
- 1 December 2024
- Published by Periodic Publication Moldovan Journal of Health Sciences in Moldovan Journal of Health Sciences
- Vol. 11 (4) , 62-66
A case report of primary hepatic amyloidosis manifesting as severe cholestasis and acute liver failure
Introduction. Hepatic amyloidosis is characterized by the deposition of fibrillar amyloid proteins, which result from light chain amyloidosis (AL) immunoglobulin fragments, in the extracellular space and the vessel walls of the liver. A case of primary hepatic amyloidosis without evidence of a primary or secondary cause of amyloid deposition is rare. This case was unique to the Republic of Moldova, presenting a diagnostic and therapeutic challenge for clinicians. Because the liver is rarely affected, this pathology remains underdiagnosed and is associated with a reserved prognosis. Clinical case presentation. An unusual case of primary hepatic amyloidosis is reported in a previously asymptomatic 59-year-old woman who presented at admission with peripheral edema, ascites, and hepatomegaly. Biochemical tests revealed severe cholestasis with normal bilirubin levels and acute liver failure. Liver damage caused by viral hepatitis or autoimmune diseases was excluded. A percutaneous bone marrow biopsy was normal, and Bence Jones protein was negative, indicating no evidence of primary amyloidosis. The definitive diagnosis was based on liver biopsy, which revealed apple green birefringence on polarizing microscopy after positive Congo red staining. Conclusions. The reported case highlights the need to differentiate between infiltrative diseases, such as amyloidosis, when a patient presents with rapidly progressive severe cholestasis and acute liver failure. Future studies should focus on the availability of specific therapies for primary amyloidosis to improve the survival rate of these patients.
- 1 December 2024
- Published by Periodic Publication Moldovan Journal of Health Sciences in Moldovan Journal of Health Sciences
- Vol. 11 (4) , 62-66
A case report of primary hepatic amyloidosis manifesting as severe cholestasis and acute liver failure
Introduction. Hepatic amyloidosis is characterized by the deposition of fibrillar amyloid proteins, which result from light chain amyloidosis (AL) immunoglobulin fragments, in the extracellular space and the vessel walls of the liver. A case of primary hepatic amyloidosis without evidence of a primary or secondary cause of amyloid deposition is rare. This case was unique to the Republic of Moldova, presenting a diagnostic and therapeutic challenge for clinicians. Because the liver is rarely affected, this pathology remains underdiagnosed and is associated with a reserved prognosis. Clinical case presentation. An unusual case of primary hepatic amyloidosis is reported in a previously asymptomatic 59-year-old woman who presented at admission with peripheral edema, ascites, and hepatomegaly. Biochemical tests revealed severe cholestasis with normal bilirubin levels and acute liver failure. Liver damage caused by viral hepatitis or autoimmune diseases was excluded. A percutaneous bone marrow biopsy was normal, and Bence Jones protein was negative, indicating no evidence of primary amyloidosis. The definitive diagnosis was based on liver biopsy, which revealed apple green birefringence on polarizing microscopy after positive Congo red staining. Conclusions. The reported case highlights the need to differentiate between infiltrative diseases, such as amyloidosis, when a patient presents with rapidly progressive severe cholestasis and acute liver failure. Future studies should focus on the availability of specific therapies for primary amyloidosis to improve the survival rate of these patients.